Literature DB >> 15937345

Standardization and validation issues of the ELISPOT assay.

Sylvia Janetzki1, Josephine H Cox, Neal Oden, Guido Ferrari.   

Abstract

During the last 20 yr, the enzyme-linked immunospot (ELISPOT) assay has emerged as one of the most important and widely used assays to monitor immune responses in humans and a variety of other species. With the ELISPOT assay, immune cell frequencies can be measured at the single cell level without elaborate expansion or manipulation of cell populations. Its usefulness has led to its application in vaccine design and development and, most importantly, in monitoring vaccination efforts. The impact of results measured with this assay can be profound. In addition to ease of performance, repeatability and reliability are major features expected of an ELISPOT assay. The focus today is on standardization of the technique, validation strategies to comply with these required features, and accommodation of the growing demand of Good Laboratory Practice (GLP) compliance. This chapter will give the experienced scientists as well as newcomers to the field an overview over the major standardization issues for each step of the protocol. Guidelines are given on how to validate the ELISPOT performance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937345     DOI: 10.1385/1-59259-903-6:051

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

1.  Validation of increased blood storage times with the T-SPOT.TB assay with T-Cell Xtend reagent in individuals with different tuberculosis risk factors.

Authors:  Shu-Hua Wang; Samuel S Stew; Joshua Cyktor; Bridget Carruthers; Joanne Turner; Blanca I Restrepo
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

Review 2.  The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.

Authors:  Richard A Koup; Barney S Graham; Daniel C Douek
Journal:  Nat Rev Immunol       Date:  2010-12-17       Impact factor: 53.106

3.  The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

Authors:  Ana M Sanchez; Wes Rountree; Mark Berrong; Ambrosia Garcia; Alexandra Schuetz; Josephine Cox; Nicole Frahm; Mark Manak; Marcella Sarzotti-Kelsoe; M Patricia D'Souza; Thomas Denny; Guido Ferrari
Journal:  J Immunol Methods       Date:  2014-03-28       Impact factor: 2.303

4.  Toward Optimal Cryopreservation and Storage for Achievement of High Cell Recovery and Maintenance of Cell Viability and T Cell Functionality.

Authors:  Stephanie Angel; Hagen von Briesen; Young-Joo Oh; Marko K Baller; Heiko Zimmermann; Anja Germann
Journal:  Biopreserv Biobank       Date:  2016-10-28       Impact factor: 2.300

5.  The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections.

Authors:  Michael D Howell; Peisong Gao; Byung Eui Kim; Leighann J Lesley; Joanne E Streib; Patricia A Taylor; Daniel J Zaccaro; Mark Boguniewicz; Lisa A Beck; Jon M Hanifin; Lynda C Schneider; Tissa R Hata; Richard L Gallo; Mark H Kaplan; Kathleen C Barnes; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2011-07-18       Impact factor: 10.793

6.  Response definition criteria for ELISPOT assays revisited.

Authors:  Z Moodie; L Price; C Gouttefangeas; A Mander; S Janetzki; M Löwer; M J P Welters; C Ottensmeier; S H van der Burg; Cedrik M Britten
Journal:  Cancer Immunol Immunother       Date:  2010-06-15       Impact factor: 6.968

7.  Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Authors:  Jeffrey R Currier; Lynee M Galley; Holger Wenschuh; Vivian Morafo; Silvia Ratto-Kim; Clive M Gray; Leonard Maboko; Michael Hoelscher; Mary A Marovich; Josephine H Cox
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

8.  Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.

Authors:  Yuanxin Xu; Valerie Theobald; Crystal Sung; Kathleen DePalma; Laura Atwater; Keirsten Seiger; Michael A Perricone; Susan M Richards
Journal:  J Transl Med       Date:  2008-10-22       Impact factor: 5.531

9.  Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Authors:  A Mander; C Gouttefangeas; C Ottensmeier; M J P Welters; L Low; S H van der Burg; C M Britten
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

10.  Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:  Sylvia Janetzki; L Price; C M Britten; S H van der Burg; J Caterini; J R Currier; G Ferrari; C Gouttefangeas; P Hayes; E Kaempgen; V Lennerz; K Nihlmark; V Souza; A Hoos
Journal:  Cancer Immunol Immunother       Date:  2009-11-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.